High cross-reactivity of hypervariable region 1 antibody of hepatitis C virus is associated with early virological response in chronic hepatitis C patients undergoing antiviral therapy
10.3760/cma.j.issn.1009-9158.2012.07.011
- VernacularTitle:慢性丙型肝炎患者第一高变区抗体的交叉反应性与抗病毒治疗早期病毒应答的关系
- Author:
Wei HUI
;
Xinhui GUO
;
Yan YAN
;
Bingshui XIU
;
Heqiu ZHANG
;
Zhuo LI
- Publication Type:Journal Article
- Keywords:
Hepatitis C virus;
Hypervariable region 1;
Cross-reactivity;
Quasipecies;
Antiviral therapy
- From:
Chinese Journal of Laboratory Medicine
2012;35(7):630-633
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo discuss the relationship between the cross-reactivity of antibody against the hypervariable region 1 ( HVR1 ) of hepatitis C virus and early viral response ( EVR ) in patients undergoing antiviral therapy.MethodsBy ELISA and HCV HVR1 antibody cross-reactivity matrix reagent,the differences of anti-HCV hypervariable region antibody were tested in baseline serum from 46 patients with chronic hepatitis C before antiviral therapy.HCV genotyping and HCV RNA were analyzed by RT-PCR method.The HCV RNA assay was done at three time points:before treatment,pegylated interferon in combination with ribavirin therapy for 12 and 48 weeks.ResultsIn 46 cases of chronic hepatitis C patients,there were 16 cases with HCV 2a type,30 cases with l b and 33 patients obtained EVR.The EVR incidence of type 2a[ 93.8％ ( 15/16 ) ] was higher than that of type 1 b[ 60.0％ (18/30),x2 =4.316,P ＜ 0.05 ].In the EVR group of type 1b chronic hepatitis C patients,the positive number of average multi-target HVR1 antigen was ( 12 ± 4),which was significantly higher than that in the Non-EVR patients [ (7 ± 5 ),t =2.797,P ＜0.01 ].Bv the Fisher exact test,it was showed that patients'serum response to HVR1 antigens numbered 001,003,009,013,016 were higher in EVR group than those in non-EVR group,with statistically significant (P ＜ 0.05 ).ConclusionThe cross-reactivity of HVR1 antibody may play an important role in predicting the effectiveness of antiviral therapy.
